Compare RXRX & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXRX | ENOV |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | 7802 |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.0B |
| IPO Year | 2021 | 2008 |
| Metric | RXRX | ENOV |
|---|---|---|
| Price | $3.82 | $18.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $7.50 | ★ $47.38 |
| AVG Volume (30 Days) | ★ 17.2M | 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $74,681,000.00 | N/A |
| Revenue This Year | $12.11 | $6.36 |
| Revenue Next Year | $82.52 | $5.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.77 | $17.30 |
| 52 Week High | $7.18 | $34.28 |
| Indicator | RXRX | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 37.86 |
| Support Level | $2.90 | $17.30 |
| Resistance Level | $4.05 | $27.20 |
| Average True Range (ATR) | 0.24 | 0.94 |
| MACD | 0.03 | 0.23 |
| Stochastic Oscillator | 69.16 | 45.19 |
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.